Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon

Cancer Gene Therapy

Volumn 4, Issue 1, 1997, Pages 33-41

  Abdel Wahab, Zeinab ^a   Dar, Mohammed ^a   Osanto, Susanne ^a,c   Fong, Timothy ^b   Vervaert, Carol E ^a   Hester, Dina ^a   Jolly, Douglas ^b   Seigler, Hilliard F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

B16 melanoma; C57BL 6 mice; Cytokine genes; Immunotherapy; Malignant melanoma; Transduction

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; INTERLEUKIN 2;

ANIMAL; ARTICLE; C57BL MOUSE; EXPERIMENTAL MELANOMA; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; MOUSE; PATHOLOGY; SECRETION;

ANIMALS; CANCER VACCINES; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; LUNG NEOPLASMS; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC;

EID: 0030636781     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz S. Regression of established pulmonary metastases and subcutaneous tumor mediated by systemic administration of high-dose recombinant IL-2.J Exp Med. 1991;161:1169-1188.
2. Rosenberg SA, Lotz MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med. 1987;316:889-896.
3. Wagstaff J, Smith D, Nelmes P, Loynds P, Crowther D. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumors. Cancer Immunol Immunother. 1987;25:54-58.
4. Lotz M, Matory YL, Rayner AA, Ettinghausen SE, Seipp CA, Rosenberg SA. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58:2764-2772.
5. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
6. Abdel-Wahab Z, We-Ping L, Osanto S, et al. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol. 1994;159:26-39.
7. Porgador A, Gansbacher B, Bannerji R, et al. Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int J Cancer. 1993;53:471-477.
8. Saito S, Banneiji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 1994;54:3516-3520.
9. Dar M, Abdel-Wahab ZA, Vervaert C, Darrow T, Barber J, Seigler HF. Transduction with the murine interferon gamma gene leads to long-term immunological memory. Ann Surg Oncol. 1996;3:247-254.
10. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
11. Golumbek P, Lazenby A, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
12. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
13. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma-cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
14. Abdel-Wahab Z, Dar M, Hester D, et al. Effect of irradiation on cytokine production, MHC antigen expression and vaccine potential of interleukin-2 and gamma interferon gene-modified melanoma cells. Cell Immunol. 1996;171:246-254.
15. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon gamma in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
16. Schmidt W, Schweighoffer T, Herbst E, et al. Cancer vaccines: the interleukin-2 dosage effect. Proc Natl Acad Sci USA. 1995;92:4711-4714.
17. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumorbearing mice with two types of IFN gamma gene-inserted tumor cells. J Immunol. 1993;150:1458-1470.
18. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med. 1993; 177:1127-1134.
19. Seigler H, Darrow T, Abdel-Wahab Z, Gangavalli R, Barber J. Clinical protocol: a phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther. 1994;5:761-777.
20. Osanto S, Brouwenstyn N, Vaessen N, Figdor CG, Melief CJM, Scrier PI. Clinical protocol: immunization with IL-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum Gene Ther. 1993;4:323-330.
21. Howard B, Burrascano M, McCallister T, et al. Retrovirusmediated gene transfer of the human gamma-IFN gene: a therapy for cancer. Ann NY Acad Sci. 1994;716:167-187.
22. Abdel-Wahab Z, Osanto S, Darrow T, et al. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther. 1994;1: 171-179.
23. Brennan GL, Kronenberg LH. Automated bioassay of interferons in microtest plate. Biotechniques. 1983;1:78-82.
24. Baron S, Coppenhaver DH, Dianzani F, et al. Introduction to the interferon system. In: Baron S, Coppenhaver DH, Dianzani F, et al, eds. Interferon, principles, and medical applications. Galveston, TX: University of Texas, 1992:1-15.
25. + T cells against wild type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
26. Rees RC, Wiltrout RH. The biology and clinical applications of interleukin-2. Immunol Today. 1990;11:11-13.
27. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989;47:187-232.